Clinical trials: Adult Atopic Dermatitis
Chronic Hand Eczema
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise…
- Trial name
- DELTA FORCE (NCT05259722)
- Testing
- Delgocitinib, Toctino
- Where
- 102 sites in Austria, Canada and 8 more
- Volunteers
- 513 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis
Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of pimecrolimus cream will be evaluated in Japanese adult patients with atopic…
- Trial name
- NCT00232011
- Testing
- Pimecrolimus Cream 1%
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Novartis
Atopic Dermatitis
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
The purpose of this study is to see how different forms of a medicine called PF-08049820 move through the body when taken by mouth.
- Trial name
- NCT07172321
- Testing
- PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.
Moderate to Severe Atopic Dermatitis
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
- Trial name
- NCT05549947
- Testing
- SHR-1819
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
- Trial name
- NCT05984784
- Testing
- IMG-007
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Inmagene LLC
Atopic Dermatitis
A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT02376049
- Testing
- Pimecrolimus cream, Betamethasone dipropionate cream, Clobetasol propionate cream
- Where
- 2 sites in Canada, Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Dermatitis, Atopic
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
To assess the long term safety and efficacy of treatment with BI 655130 in patients with AD who have completed and have responded to treatment in the parent study 1368-0032
- Trial name
- NCT04086121
- Testing
- Spesolimab
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Moderate-to-severe Atopic Dermatitis
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of SHR-1819 in adult patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07321951
- Testing
- SHR-1819 Injection, SHR-1819 Injection Blank Preparation
- Where
- 2 sites in China
- Volunteers
- 201 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Atopic Dermatitis
Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)
The purpose of this trial is to test if treatment with the trial drug, tralokinumab, can affect the body's immune response to vaccines.
- Trial name
- ECZTRA 5 (NCT03562377)
- Testing
- Tralokinumab, Tdap vaccine, Meningococcal vaccine
- Where
- 51 sites in United States, Canada
- Volunteers
- 215 people
- Sponsor
- LEO Pharma
Atopic Dermatitis, Rheumatoid Arthritis
MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis
This is a Phase Ia/Ib Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis and participants with Mild to Moderate Rheumatoid Arthritis.
- Trial name
- NCT04815148
- Testing
- MH004 Ia(0.1%), MH004 Ia(0.3%), MH004 Ia(1%)
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Minghui Pharmaceutical Pty Ltd
Atopic Dermatitis
Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
This study determines the Maximum Tolerable Dose (MTD) by maximum BSA percentage treated and evaluates safety and efficacy of 1.1% w/w AMTX-100 CF versus placebo (vehicle).
- Trial name
- NCT04313400
- Testing
- 1.1% w/w AMTX-100 CF-part1, 1.1% w/w AMTX-100 CF3-part2
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Amytrx Therapeutics, Inc.
Eczema
A 47 Hour Occlusive Cutaneous Skin Patch Test on Adult Subjects With Dry/Atopic Skin
This is an open label, non-comparative investigation to determine the tolerance of Eczema Repair Emollient on healthy subjects with dry/atopic and very dry/atopic skin.
- Trial name
- NCT02620293
- Testing
- Eczema Repair Emollient
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Atopic Dermatitis
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
This is a multi-center, randomized, double-blind, parallel, placebo-controlled phase 2 clinical study. A total of 403 adult participants with moderate to severe AD are planned to be enrolled to evaluate efficacy, safety, PK…
- Trial name
- NCT07330934
- Testing
- Dupilumab, IBI356
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.
The purpose of the study is to evaluate the Safety, Tolerability, and Pharmacokinetics of LNK01004 ointment (0.3%, 1.0%, and 1.5%) vs vehicle twice daily (BID) in Adults Patients with Atopic Dermatitis.
- Trial name
- NCT06553287
- Testing
- LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, LNK01004 ointment 1.5%
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Atopic Dermatitis
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).
- Trial name
- NCT03736967
- Testing
- REGN3500, Dupilumab, REGN3500 + Dupilumab Combo
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
A randomized, double-blind, placebo-controlled trial design was used to assess the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, and immunogenicity of TQH2722 injection in healthy subjects.
- Trial name
- NCT05409326
- Testing
- TQH2722 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Atopic Dermatitis (AD)
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn if drug LT-002-158 works to treat moderate-to-severe atopic dermatitis in adults. It will also learn about the safety of drug LT-002-158.
- Trial name
- NCT07895615
- Testing
- LT-002-158
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD5 (NCT03435081)
- Testing
- Baricitinib
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01859988
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 380 people
- Sponsor
- Regeneron Pharmaceuticals